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ABSTRACT 
 
Aim: This study was undertaken to determine and compare the efficacy and toxicity of chronomodulated FOLFOX 
+ radiotherapy to conventional FOLFOX + radiotherapy in the neoadjuvant setting of locally advanced rectal cancer. 
Materials and methods: A total of 44 patients were randomly assigned to the two arms with 24 in 
chronomodulated arm (Arm A) and 20 in conventional arm (Arm B).Four cycles of FOLFOX chemotherapy 
followed by radiotherapy were given to18 patients in Arm A and all the 20 patients in Arm B completed the 
treatment. All the patients were evaluated for surgery. Tumor down staging and toxicity profile were compared. 
Results: tumor down staging and sphincter preservation rates were similar in both the arms. Incidence of grade-III 
and grade-IV stomatitis, diarrhea and paresthesia was more in Arm B than in Arm A. Nausea was the most common 
symptom in both the treatment arms.83% patients in Arm A and 86% patients in Arm B experienced nausea at some 
point during the treatment.  Diarrhea was more common in Arm B with 15 % patients experiencing grade 3-4 
diarrhea when compared to 5.55% in Arm A. Stomatitis was more common in Arm B with 10% patients 
experiencing grade 3-4 toxicity as compared to 5.5% in Arm A. It was observed with increased frequency in Arm B 
with 7(20%) patients experiencing grade 3 sensory neuropathy compared to 2(11.1%) in Arm A. The incidence of 
hematological toxicities was similar in both arms with only grade 1 and 2 neutropenia occurring in both the arms. 
The incidence of leucopenia was greater in the conventional arm (Arm B).Conclusions: we conclude that the 
administration of Chronomodulated FOLFOX followed by radiotherapy has a better toxicity profile and hence better 
tolerance and similar tumor down staging when compared to conventional FOLFOX and radiotherapy in the 
neoadjuvant treatment of locally advanced carcinoma rectum.  
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Introduction 
Globally, colorectal cancer is the third commonest 
cancer in men since 1975. In the developed countries it 
is now the second most common cancer after lung 
cancer in men. Incidence rates in Africa, except South 
Africa and South and Central Asia including India are 
quite low (2 to 8 per 100,000). Colorectal cancer 
burden has been steadily rising in women. It was the 
fourth commonest cancer in 1975 and has reached the 
second position by 1990[1].Rectal cancer ranks 7
th
 
among the most common cancers in males and is the  
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th
 most common cancer in women in India.
i
An 
estimated 35,635 new cases of colorectal cancer 
occurred in 2006, accounting for 3.9 percent of all new 
cases of cancer[2].Age standardized incidence rate per 
100,000 populations in men ranges from 1.5 to 6.9 and 
in women it ranges from 2.5 to 7.4 in the various urban 
population based cancer registries.Error! Bookmark 
not defined. The incidence rates are low in the rural 
areas ranging from 1.6 to 2.4 in males and 1.1 to 1.3 in 
females. Out of the seven PBCRs (population based 
cancer registries) an increasing trend in the age 
adjusted annual incidence rates (AAR) in the colorectal 
cancer was observed[3]. Statistics from MNJ Institute 
of Oncology and Regional Cancer Centre from the year 
2001-2009 shows the incidence of rectal cancer to 
range from 1.12%-2.48 % of all cancers registered 
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during the ten years. Average male to female ratio is 
1.56:1.A working definition of “locally advanced 
rectal cancer” is one that cannot be resected without 
leaving microscopic or gross residual disease at the 
local site because of tumor adherence or fixation to that 
site. It includes those tumors reaching to and beyond 
the endopelvic fascia (extensive T3 and T4 
tumors).The 5 year survival rate in these patients with 
surgery alone which includes wide en bloc resection of 
adjacent organs is only 19-33 %.Error! Bookmark 
not defined.About 75% patients fail locally, therefore 
good local control is essential to achieve good survival 
rate.Surgery remains the mainstay of treatment for 
rectal cancer. Transmural involvement and node 
positive disease pose a challenge to surgery as it is 
difficult to achieve free circumferential margins even 
with total mesorectal excision (TME). Neoadjuvant 
radiotherapy, by down staging the tumor, improves the 
surgical outcome and reduces the local failure rates but 
does not alter the overall survival. 
 
Materials and methods 
 
The patients treated between October 2008 and April 
2010 at MNJ Institute of Oncology and Regional 
Cancer Center with the following inclusion and 
exclusion criteria were taken into the study. 
Inclusion Criteria: Age less than 75 years Adeno 
carcinoma of rectum proven by biopsy, Stage III or 
beyond rectal cancer either clinically or image logy 
(CECT abdomen, trans rectal ultrasound),ECOG 
performance status of 0-2, Hematological parameters 
with total leukocyte count of>4000cells/mm
3
, platelet 
counts of >1.5 lakhs /mm
3. 
Exclusion Criteria: Age greater than 75 years , Patients 
with demonstrable  distant metastasis at the start of 
treatment , Histopathology other than adenocarcinoma, 
Previous treatment for any pelvic malignancy, Poor 
performance status ECOG PS >2, Deranged 
hematological and renal parameters and Patients not 
likely to be available for follow up. 
Complete history and physical examination, Digital 
rectal examination- The distance between the anal 
verge and the lower pole of the tumor was assessed by 
digital rectal examination. 
Haematological, Radiological investigations, Endoscopic 
study and Histopathology of the tumor and grade. After 
thorough pre-treatment evaluation, the intent regarding 
the type of surgery was recorded before proceeding for 
pre-operative chronomodulated FOLFOX and 
radiotherapy or conventional FOLFOX and 
radiotherapy, by randomly assigning the patients to 
each arm. 
 
Study Design
CHEMOTHERAPY 
 
Arm A: Selected patients were explained regarding the 
course of treatment and were started on 
chronomodulated FOLFOX with Oxaliplatin 85 
mg/m
2
on day 1 administered from 0945hrs to 1600hrs 
followed by simultaneous infusion of calcium 
leucovorin in one arm and 5 fluorouracil in the other 
arm from 2200hr to 0915hr the next day for five days. 
The cycle was repeated every three weeks for four 
cycles. After chemotherapy the patients were evaluated 
for response by DRE, serum CEA, X ray chest and CT 
scan abdomen and pelvis. 
Arm B:In this group the patients were administered 
FOLFOX conventionally with Oxaliplatin 85mg/m
2
 on 
day 1 and calcium leucovorin and 5 fluorouracil from 
day 1 to day 5 repeated every 3 weeks for 4 cycles. The 
response was evaluated with DRE, CT scan of 
abdomen and pelvis, serum CEA and x- ray chest. 
 Radiotherapy to the pelvis by external beam 
with either Cobalt 60 or Linear accelerator was planned 
by either 4 field, 3field or 2 field techniques to a total 
dose of 45-50.4 Gy. Patients were simulated on a 
Ximatron x-ray simulator and planned with the 
following field borders: 
 Superior margin: Lower border of L5 or L5 – SI 
junction or 1.5 cm above the sacral promontory. 
 Lateral margin: 1.5 – 2 cm lateral to the true bony 
pelvis. 
 Inferior margin: Lower border of the obturator 
foramen in case of upper rectal cancers or 2 – 5 cm 
below the most inferior extent of the gross tumor. 
FOLF OX 
CYCLE 1  
FOLFOX 
CYCLE 2  
FOLFOX 
CYCLE 3 
FOLFOX 
CYCLE 4 
RADIATION 
THERAPY 
SURGERY 
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 Lateral Fields: The upper and lower margins remain 
the same. The anterior margin was at least 4 cm 
anterior to the rectum, as determined by the rectal 
contrast. The posterior field margin is 1to1.5cm behind 
the sacrum to include whole of the sacral canal.All the 
patients from both the arms were taken up for surgery 
after 4-6 weeks of radiotherapy. Total mesorectal 
excision coupled with low anterior resection or 
abdominoperineal resection or pelvic exenteration was 
planned based on preoperative evaluation.During the 
course of the radiotherapy or concurrent chemo 
radiation and in the post-RT follow up period the 
patients were examined regularly for acute toxicity 
using Common Toxicity Criteria (Ver-2)
108
. Toxicities 
were managed symptomatically with analgesics, 
intravenous fluids, and antibiotics. In patients with 
grade-III or IV toxicity, treatment was interrupted. 
Packed cell transfusions and colony stimulating factors 
were used whenever necessary.All  the patients were 
taken up for adjuvant chemotherapy and were followed 
up regularly once in a month for 1 year and 3 monthly 
in the next 2 years and 6 monthly follow up afterwards 
with clinical examination, S.CEA, periodical CECT-
abdomen, colonoscopy. 
 
Results 
 
Patients treated from October 2008 to April 2010 were 
analyzed. A total of 294 rectal cancer patients were 
treated during the period. Of the 294 patients 
132(44.8%) patients were treated with post-operative 
radiotherapy.47 (15.9%) patients presented with 
metastatic disease at diagnosis. Three patients had 
other than adenocarcinoma histology.112 (38%) 
patients received neoadjuvant treatment.Of the 112 
patients who received neoadjuvant treatment 63 
received only concurrent chemo radiation. Of the 
remaining 49 patients 5 patients did not fulfil the 
inclusion criteria ( 2 had renal failure ,PS of 2 patients 
was 3-4 and one patient was irradiated previously).A 
total of 44 patients fulfilled the inclusion criteria and 
were included in the study. 24 patients were included 
in the Chronomodulated arm (Arm A) and 20 patients 
in the conventional arm (Arm B).Of the 24 patients in 
Arm A, 6(25%) patients received incomplete treatment 
(3 patients developed distant metastases while on 
treatment and 3 patients refused further treatment after 
2 cycles of chemotherapy).So a total of 18(75%)  
patients completed treatment in Arm A. 
 
 Fig 1: Study population. 
Total no of. cases of 
carcinoma rectum  in 
the study period. 
N= 294 
Postoperative RT 
n1 = 132 (44.8%) 
Neoadjuvant   
n2 = 112(38%) 
63 patients recieved 
only concurrent 
chemoradiation  
5 patients did not 
fulfil the criteria 
44 patients were 
eligible for the study  
24 patients recieved 
chronomodulated 
chemotherapy 
Arm  A 
Total No.of patients 
completed the study 
n=18 
20 patients recieved 
conventional 
chemotherapy 
Arm B 
Total No.of patients 
completed the study 
n= 20 
Metastatic 
n3 = 47(15.9%) 
Other Histology 
n4  = 3(1.02%) 
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Table 1: Patient Profile 
Patient Characteristics              Arm-A Chronomodulated   Arm-B Conventional 
Total No of patients included in the 
study 
24 20 
Total No of patients completed the study 18(75%) 20(100%) 
Mean Age at diagnosis 42.2 yr 38.4 yr 
Sex Ratio(Male: Female) 1.4 2 
Mean distance from the anal verge  2.7 cm 3.2 cm 
Tt   Type of surgery  
AbdAbdominoperineal resection or Low 
anterior resection 
Exenteration 
 
12 
3 
1 
 
15 
2 
1 
 
 
Fig 2: Grade of the Disease in Both Arms 
Tumor downstaging 
The tumor down staging in post-operative 
histopathology is as follows: 
- Arm-A:- 16(88.9%) patients underwent significant 
down staging, 7 patients from T4 lesion to T3 and T2 
stages and 9 patients from T3 to T2. 5 patients who had 
node positive disease as per imaging studies had node 
negative disease at surgery. 
- Arm-B:-  18(90%) patients had tumor down staging. 11 
patients from T3 to T2 ,7 from T4 to T2 and 4 patient 
who was node positive became node negative at the 
time of surgery. 
SPHINCTER PRESERVATION: 
- Arm A: Of the 16 patients who underwent 
surgery,3(18.7%) had low anterior resection with 
sphincter preservation. 
- Arm B: Of the 18 patients who were operable after 
neoadjuvant treatment,2(11.1%) underwent sphincter 
preserving surgery. 
Acute toxicities:-All the toxicities were graded 
according to WHO Common Toxicity Criteria version 
2.0. 
Table 2: Incidence of Side effects 
 Grade 1 Grade 2 Grade3 Grade4 
Nausea 
Arm A  12(66.6%) 1(5.5%) 2(11.1%) - 
Arm B 14(70%) 1(3.44%) 2(10%) - 
Vomiting 
Arm A 4 2 (11.1%)        -        - 
Arm B 3 2 (10%)        -        - 
Diarrhea     
Arm A 4 1 1 0 
Arm B 5 4 3 0 
0
2
4
6
8
10
12
W.D M.D P.D
Arm A
Arm B
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Stomatitis 
Arm A - 2 1(5.5%) 0 
Arm B - 6 2(10%) 0 
Peripheral sensory neuropathy 
Arm A 3 1 2 0 
Arm B 2 4 4 0 
Hematuria 
Arm A 3 1 0 0 
Arm B 3 2 0 0 
Dysuria 
Arm A 4 3 1 0 
Arm B 5 4 2 0 
Anemia 
Arm A(Chrono) 4 2         -         - 
Arm B(Conv.) 5 3         -         - 
Leucopenia 
Arm 
A(Chrono.) 
2 0         - - 
Arm B(Conv.) 5 4         - - 
 
- Incidence of grade-III and grade-IV stomatitis, diarrhea 
and paresthesia was more in Arm B than in Arm A.  
Nausea was the most common symptom in both the 
treatment arms.83% patients in Arm A and 86% 
patients in Arm B experienced nausea at some point 
during the treatment. There was no significant 
difference in the incidence of nausea in both the arms. 
Diarrhea was more common in Arm B with 15 % 
patients experiencing grade 3-4 diarrhea when 
compared to 5.55% in Arm A.All the patients with 
severe symptoms were managed accordingly with 
intravenous fluids. Stomatitis was more common in 
Arm B with 10% patients experiencing grade 3-4 
toxicity as compared to 5.5% in Arm A. It was 
observed with increased frequency in Arm B with 
7(20%) patients experiencing grade 3 sensory 
neuropathy compared to 2(11.1%) in Arm A. The 
incidence of hematological toxicities was similar in 
both arms with only grade 1 and 2 neutropenia 
occurring in both the arms. The incidence of 
leucopenia was greater in the conventional arm (Arm 
B). 
- Discussion 
-  
- Surgery forms the main stay of cure in carcinoma 
rectum. However in locally advanced rectal cancer, 
results of surgery as the lone modality of treatment 
showed increased incidence of local recurrence. Hence 
adjuvant therapy in the form of pre-operative or post-
operative radiation therapy with or without 
chemotherapy has become the accepted modality of 
treatment.The most important information regarding 
the use of pre-operative radiation therapy and its 
advantages compared with surgery alone comes from 
the Swedish rectal cancer trial and the Dutch TME 
study. The Swedish rectal cancer study group 
randomized 1168 patients to preoperative short course 
radiotherapy(25 Gy in 5 fractions)followed by surgery 
after 1 week in Arm A or only surgery in Arm B with a 
median follow up of 7 years. 
Table 3: Results of  Study Group 
Study related to our study Arm A Arm B P value 
Swedish Rectal Cancer Study 
Treatment given Pre op RT (25Gy in 5#) 
followed by surgery 
Surgery alone  
Local recurrence rate 11% 27% <0.001 
5 yr Overall survival 58% 48% 0.004 
The Dutch TME Study 
Treatment given Preop RT+TME TME alone  
2 yr OS 82% 81.8% 0.84 
2 yr local recurrence 2.4% 8.2% <0.001 
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This was the only study that showed a significant 
survival benefit after the use of pre-operative radiation 
therapy[4,5].A meta-analysis  of 14 randomized control 
trials done over 2 decades comparing  pre-operative 
RT+ surgery and surgery alone  showed reduction in 
cancer related mortality(CI 0.38-0.62) and local 
recurrence rates in RT + surgery group but there was 
no change in the rate of distant metastasis[6].After the 
advent of the technique and the concept of Total 
Mesorectal Excision (TME), the incidence rates of 
local recurrence drastically fell down. Studies have 
shown that the surgical technique and the experience of 
the operating surgeon are the most important factors in 
determining the local recurrence after surgery. The 
Dutch TME study Number of patients were 1861 
patients with resectable rectal cancer. This showed that 
pre-operative radiation therapy helps in reducing the 
local recurrence rates[7].There are some biological, 
functional and physical advantages with preoperative 
radiotherapy, which include decreased tumor seeding at 
the time of surgery, increased radio sensitivity of the 
tissues as compared to the postoperative hypoxic 
tissues, no postoperative small bowel fixation in the 
pelvis and hence less chances of complications and 
increased chances for a sphincter sparing surgery. But 
the major disadvantage is potential over treatment of 
the early stage and more disseminated presentations of 
the disease. 
Pre-operativeVs.post-operative radiotherapy;There 
has been a debate regarding the timing of 
radiotherapy. Several studies were done comparing 
the pre-operative and post-operative approaches. 
German rectal cancer study group randomly 
assigned 421 patients to receive preoperative chemo 
radiotherapy and 402 patients to receive postoperative 
chemo radiotherapy. The conclusion was that 
Preoperative chemo radiotherapy, as compared with 
postoperative chemo radiotherapy, improved local 
control and was associated with reduced toxicity but 
did not improve overall survival[8]. 
Studies such as FFCD9203[9], EORTC 22921[10-
12]comparing radiotherapy alone and chemo radiation 
have been conducted and these found no difference in 
sphincter preservation rates though the tumor down 
staging was more significant in the chemo radiation 
arms. The timing of chemotherapy was suggested to 
have better compliance rates when given in the 
preoperative setting owing to lesser toxicity.The issue 
regarding the time gap between the end of pre-
operative therapies and sphincter saving surgery was 
dealt with in 4 randomized studies namely the Polish 
rectal cancer group trial, German randomized trial[13], 
NSABBP R-03 trial[14], Lyon trial[15]because of the 
fact that rectal cancer shrinks slowly. All the studies 
showed no significant benefit in rates of sphincter 
preservation with delayed surgery.The role of induction 
chemotherapy prior to preoperative chemo radiation 
therapy has been explored both in poor-risk patients 
and conventional risk patients with locally advanced 
rectal cancer. The theoretical advantages of induction 
chemotherapy include the potential for improved tumor 
regression as well as improved treatment compliance 
allowing for the delivery of full systemic doses of 
chemotherapy.In a study conducted by The Royal 
Marsden Hospital 4 cycles of induction CapeOx 
followed by capecitabine CXRT (54 Gy)was 
administered in high risk rectal cancer patients. It was 
associated with a high rate of R0 resection (96%) and a 
pCR rate of 20%[16]The Spanish Gruppo Cancer de 
Recto 3 Study was a randomized phase II study that 
was built upon the lessons learned from the Royal 
Marsden experience.108 patients with locally advanced 
rectal cancer randomized study (Table-3)[17]Calvo et 
al[18]studied the incidence of pT0 down staging in 
locally advanced rectal cancer when treated with 
induction Oxaliplatin/5FU/LV when compared to 
concurrent chemo radiation alone.Studies on 
chronomodulated FOLFOX Levi et al performed a 
randomized phase II study comparing conventional and 
chronomodulated infusion of FOLFOX[19]. 
 Arm A: Conventional FOLFOX : 5 d continuous 
infusion Q21days 
 Arm B: Chronomodulated FOLFOX :Oxaliplatin 
administered between 1015h and 2145h                                                                                          
5FU+LV administered from 2215 to 0945 h                                            
This trial provided clinical data to corroborate the 
potential of chronomodulation with these agents and 
led to additional trials. 
Levi et al. pooled and updated data from this trial and a 
second study. In the combined analysis, 140 patients 
were treated with the flat infusion and 138 with the 
chronomodulated infusion schedule. The objective 
response rates were 30% vs 51% and the resection rate 
was 13% vs 23%. Median survival was 16.5 vs 18.6 
mo and 13% vs 15%of patient were alive at 5 yr after 
study entry[20]Another French group has published 
work using chronomodulated drug delivery 
schedules[21] In this trial, 50 patients with metastatic 
colorectal cancer, 37 of whom were pretreated, were 
given a regimen consisting of 300 mg/m2/d LV, 700 
mg/m2/d 5-FU, and 25 mg/m2/d Oxaliplatin for 4 d 
every 2 wk. The drugs were delivered via a pump 
programmed to maximize peak flow rates of 
Oxaliplatin at 4:00 PM and 5-FU at 4:00 AM. The 
median 5-FU drug dose was 3200 mg/m2 per course, 
indicating that dose escalation was possible in many 
patients. The response rate was 48%, including a 40% 
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response rate in 5-FU-pretreated patients. Toxicity was 
moderate with grade 3 hand–foot syndrome in 14%, 
peripheral neuropathy in28%; grade 3–4 nausea and 
vomiting in 36%, and diarrhea in 7%. 
 
Giachetti et al[22] conducted a trial to compare the 
response rates and toxicity profiles of chronomodulated 
5FU+LV Vs chronomodulated Oxaliplatin+5FU+LV in 
locally advanced and metastatic colorectal cancer[22]
 
Arm A: 5-FU (700 mg/m2/d) and LV (300 mg/m2/d) 
infused from 2215 to 0945 h, peak delivery by 
programmable pump at 0400 h, d 1–5, q 21 d 
Arm B: Oxaliplatin (125 mg/m2/d) infused from 1000 
to 1600 h, d 1, q 21 d and 5-FU (700 mg/m2/d) and CF 
(300 mg/m2/d) delivered as in arm A, d 1–5, q 21 d. 
Table 4: Results (Intent to treat)Error! Bookmark not defined. 
 Arm 1:5FU/LV Arm 2:5FU/LV/OXAL 
No. of patients 100 100 
No. of patients evaluated 92 88 
Overall response rate 16% 53%(p=<0.001) 
CR 0/100 3/100 
PR 16/100 50/100 
Stable 45/100 24/100 
 
Toxicities were mild in Arm 1 with <5% patients 
experiencing grade 3-4 toxicities while 43%patients in 
Arm 2 experienced grade3-4 diarrhoea and 25% had 
grade 3-4 nausea/vomiting. In summary, this 
randomized multicenter phase III trial Showed 
threefold increase in response rates when Oxaliplatin 
was added to 5FU/LV. Overall, the Oxaliplatin-
containing arm did have more toxicity. The most 
common side effect was diarrhoea, and the cumulative 
dose-limiting toxicity was sensory peripheral 
neuropathy.EXPERT study (Oxaliplatin Capecitabine 
and preoperative radiotherapy followed by TME) 
included 105 patients of poor risk rectal cancer. 
Patients were treated with four cycles of Oxaliplatin 
130mg/m
2
 and Capecitabine 2000mg/m
2
/d D1-D14 
repeated every 3 weeks followed by concurrent chemo 
radiation to a total dose of 54 Gy with capecitabine 
1620mg/m
2
/d. Resolution of symptoms was observed 
in majority of patients at a median of 32 days from the 
start of chemotherapy. Radiological response rate was 
88% following neoadjuvant chemotherapy and 
increased to 97%after neoadjuvant chemo radiation. 
Complete radiological response was observed in 20% 
at the end of chemo radiation. There was no 
progressive disease during treatment,.R0 resection was 
achieved in 99% of patients. 16(24%) patients had 
PCR. Tumor down staging was observed in 76% of 
patients. 
 
Conclusion 
Tumor down staging and toxicity profile were 
compared. In our study the tumor down staging and 
sphincter preservation rates were similar in both the 
arms. Grade 3-4 toxicities of stomatitis, diarrhea and 
paresthesias were more common in the conventional 
arm Thus we conclude that the administration of 
Chronomodulated FOLFOX followed by radiotherapy 
has a better toxicity profile and hence better tolerance 
and similar tumor down staging when compared to 
conventional FOLFOX and radiotherapy in the 
neoadjuvant treatment of locally advanced carcinoma 
rectum. But given the small sample size in each group 
further studies with larger number of patients are 
required to come to a statistically significant 
conclusion 
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